Biotech
A Drug Just Beat Keytruda on Survival for the First Time — by 8.2 Months
Ivonescimab lived a median 30.8 months vs Keytruda's 22.6 in a head-to-head lung cancer trial — the first clear survival win over the world's best-selling drug.
Topic
Oncology
The latest Oncology news and analysis from Tech Arcade.
Biotech
A Pill Just Doubled Survival in Pancreatic Cancer. The FDA Cleared It in About a Month — at $477,000 a Year.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
Biotech
Rejected Twice, Approved on the Third Try: The Tumor-Injected Virus That Just Cleared the FDA
After two rejections, Replimune's tumor-injected virus Tudriqev won accelerated FDA approval on August 6 — a 24.2% response rate in melanoma that had beaten standard immunotherapy.
Biotech
Celcuity's First-Ever Drug Cut Breast-Cancer Progression 76% — and Wall Street Sold It Anyway
Celcuity's first FDA drug, REVTORPYK, cut breast-cancer progression risk 76% and stretched median control from 2.0 to 9.3 months — yet the stock slid on a delayed launch and rough side effects.